Riskpilot← Back to searchSign inGet full accessPalmpharma AB
ABDissolvedOrg 5568026115Business and other management consultancy activities · NACE 7022Est. 20100 employees
Revenue 2021
SEK 0
EBITDA margin
—
+38% vs 2020
Equity ratio
78.0%
Financial strength
Net profit 2021
SEK -18K
+36% vs 2020
| Revenue | SEK 0 | — |
| EBITDA | SEK -18K | +38% |
| Net profit | SEK -18K | +36% |
| Total assets | SEK 91K | -17% |
| Equity | SEK 71K | -20% |
| Employees | 0 | — |
Legal name
Palmpharma AB
Org number
5568026115
Legal form
Aktiebolag
NACE code
7022 · Business and other management consultancy activities
Founded
20 mars 2010
Share capital
SEK 0
Employees
0
VAT registered
No
Audit selected
No
Last report
2021-03-31
Financial year
January – December
Company purpose
Bolaget har till föremål för sin verksamhet att förvalta aktier i bolag samt bedriva konsultverksamhet inom ekonomi, management och administration samt därmed förenlig verksamhet.
Address
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 |
|---|---|---|---|---|---|---|
| Revenue | — | 0 | 0 | 0 | 0 | 0 |
| Staff expenses | — | — | — | — | — | — |
| EBITDA | 2 | −11 | 1 | −105 | −29 | −18 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | −0 | −0 |
| EBIT | 2 | −11 | 1 | −105 | −29 | −18 |
| Net financials | — | −29 | 18 582 | −333 | — | — |
| Profit before tax | 2 | −40 | 18 583 | −437 | −28 | −18 |
| Tax | −0 | −0 | −0 | −0 | −0 | −0 |
| Net profit | 2 | −40 | 18 583 | −437 | −28 | −18 |
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 |
|---|---|---|---|---|---|---|
| Total assets | 2 509 | 2 509 | 18 701 | 150 | 109 | 91 |
| Equity | 82 | 41 | 18 624 | 117 | 89 | 71 |
| Long-term debt | 2 339 | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 88 | 2 467 | 77 | 33 | 20 | 20 |
| Total debt | 2 427 | 2 467 | 77 | 33 | 20 | 20 |
EBITDA margin
-1800000.0%
This company
15.8%
Market median
-11392505% vs market
20162021
Equity ratio
78.0%
This company
38.2%
Market median
+104% vs market
20162021
Return on equity
-25.4%
This company
18.4%
Market median
-238% vs market
20162021
Net profit margin
-1800000.0%
This company
8.1%
Market median
-22222322% vs market
20162021
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20162021
Debt / equity
0.28×
This company
0.62×
Market median
+55% vs market
20162021
- Annual report 2021Filed via Bolagsverket / SCB · Period 2020-04-01 – 2021-03-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2019-04-01 – 2020-03-31
- Annual report 2019Filed via Bolagsverket / SCB · Period 2018-04-01 – 2019-03-31
- Annual report 2018Filed via Bolagsverket / SCB · Period 2018-01-01 – 2018-03-31
- Annual report 2017Filed via Bolagsverket / SCB · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via Bolagsverket / SCB · Period 2016-01-01 – 2016-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
SM Authorized Recipient of Service | Authorized Recipient of Service | 2020 | — | — |
MA | Audit | 2021 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Deputy Board Member | 2020 | — | — | |
| Board of Directors | 2020 | — | — | |
| Board of Directors | 2020 | — | — | |
| Chairman | 2020 | — | — |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Palmpharma AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Syed Mahmood Shah | Authorized Recipient of Service | 0 companies |
| Mats Anders Peter Törnros | Audit | 0 companies |
| Shahbaz Riaz | Deputy Board Member | 0 companies |
| Poul Schmidt | Board of Directors | 0 companies |
| Imtiaz Ahmed | Board of Directors | 0 companies |
| Shahzad Riaz | Chairman | 0 companies |